Abstract:CCR2 is predominantly expressed by monocytes/macrophages with strong proinflammatory functions, prompting the development of CCR2 antagonists to dampen unwanted immune responses in inflammatory and autoimmune diseases. Paradoxically, CCR2-expressing monocytes/macrophages, particularly in tumor microenvironments, can be strongly immunosuppressive. Thus, targeting the recruitment of immunosuppressive monocytes/macrophages to tumors by CCR2 antagonism has recently been investigated as a strategy to modify the tumor microenvironment and enhance anti-tumor immunity. We present here that beneficial effects of CCR2 antagonism in the tumor setting extend beyond blocking chemotaxis of suppressive myeloid cells. Signaling within the CCL2/CCR2 axis shows underappreciated effects on myeloid cell survival and function polarization. Apart from myeloid cells, T cells are also known to express CCR2. Nevertheless, tissue homing of Treg cells among T cell populations is preferentially affected by CCR2 deficiency. Further, CCR2 signaling also directly enhances Treg functional potency. Thus, although Tregs are not the sole type of T cells expressing CCR2, the net outcome of CCR2 antagonism in T cells favors the anti-tumor arm of immune responses. Finally, the CCL2/CCR2 axis directly contributes to survival/growth and invasion/metastasis of many types of tumors bearing CCR2. Together, CCR2 links to two main types of suppressive immune cells by multiple mechanisms. Such a CCR2-assoicated immunosuppressive network is further entangled with paracrine and autocrine CCR2 signaling of tumor cells. Strategies to target CCL2/CCR2 axis as cancer therapy in the view of three types of CCR2-expessing cells in tumor microenvironment are discussed.

Potential Roles and Targeted Therapy of the CXCLs/CXCR2 Axis in Cancer and Inflammatory Diseases

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting

The CXCL8-CXCR1/2 pathways in cancer

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets

Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy

The Role of CXCR3 and Its Ligands in Cancer

The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine

CXCL6: A potential therapeutic target for inflammation and cancer

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

Regulative Role of the CXCL13-CXCR5 Axis in the Tumor Microenvironment

Clinical Significance of CXCL13/CXCR5 Axis in Human Cancers

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

CXCL13-CXCR5 axis：regulation in inflammatory diseases and cancer

CXCL3: A key player in tumor microenvironment and inflammatory diseases

Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer